Monitoring Agency Report for quarter ended 31st March, 2026.
WOCKPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
CRISIL Ratings Limited, the monitoring agency, has confirmed that Wockhardt deployed Rs 815.46 crore of its Rs 977.79 crore QIP proceeds as of March 31, 2026, with Rs 162.33 crore remaining unutilized. The company fully utilized Rs 500 crore for debt repayment and Rs 227.79 crore for general corporate purposes. However, only Rs 87.67 crore of the Rs 250 crore allocated for capital expenditure and R&D has been spent so far. The Board has extended the utilization deadline for the remaining R&D/Capex funds to March 2028 due to ongoing project timelines. No deviations from the stated objects of the QIP were reported. Unutilized funds are invested in HDFC Mutual Fund (Rs 50 crore) and Tata Mutual Fund (Rs 110.89 crore), earning Rs 12.66 crore in returns.
Positive for shareholders: debt repayment is complete and funds are being deployed as intended. The extended timeline for R&D spending may indicate slower-than-expected project execution but appears to be a planned timeline adjustment rather than a problem.